Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vineet Laboratories was -5.30% per year. The lowest was -5.30% per year. And the median was -5.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vineet Laboratories 3-Year EBITDA Growth Rate Related Terms
NSE:VINEETLAB vs DOW: 3-Year EBITDA Growth Rate Comparison
For the Chemicals subindustry, Vineet Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vineet Laboratories 3-Year EBITDA Growth Rate vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Vineet Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vineet Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Vineet Laboratories (NSE:VINEETLAB) has a 3-Year EBITDA Growth Rate of 0.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vineet Laboratories and its competitors. According to the industry distribution chart, Vineet Laboratories ranks #999999 out of 1407 companies in the Chemicals industry.
Is Vineet Laboratories' 3-Year EBITDA Growth Rate too high?
Vineet Laboratories' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Vineet Laboratories ranks #999999 out of 1407 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Vineet Laboratories has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vineet Laboratories' 3-Year EBITDA Growth Rate compare to DOW?
According to the Chemicals industry distribution chart, Vineet Laboratories ranks #999999 out of 1407 companies for 3-Year EBITDA Growth Rate. This places Vineet Laboratories in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 0.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Chemicals company?
The median 3-Year EBITDA Growth Rate among Chemicals companies is 0.80, based on 1,407 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vineet Laboratories and its competitors. For the Chemicals industry, the median 3-Year EBITDA Growth Rate is 0.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vineet Laboratories's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vineet Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vineet Laboratories (NSE:VINEETLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹14.95, compared to a current price of ₹36.33 — trading 143% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Vineet Laboratories' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vineet Laboratories (NSE:VINEETLAB), the current 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vineet Laboratories (NSE:VINEETLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vineet Laboratories stock appears to be overvalued.
The current stock price of ₹36.33 is trading 143% above its estimated GF Value™ of ₹14.95.
GuruFocus considers Vineet Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:VINEETLAB:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: ₹14.95 vs. price of ₹36.33 (143% above fair value)
No single metric tells the full story. See the NSE:VINEETLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vineet Laboratories Ltd is engaged in the business of Pharmaceutical intermediates and Fine chemicals. The products of the companies include Dimethyl phenoxy acetyl chloride, Dimethyl Phenoxy Acetic Acid, Nitrophenyl phosphate disodium salt, and others. Geographically, the company operates within India and outside India, with a majority of revenue coming from India. The company has one business segment, the manufacture of Drug Intermediates & Bulk Dugs.
38GF Score
Get the complete analysis for NSE:VINEETLAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VINEETLAB has been successfully added to your 
